University of Iowa Interventional Psychiatry Service Patient Registry
About This Trial
The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and/or after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi/genetic testing, and autonomic nervous system measures (i.e. "fight-or-flight" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient ("personalized medicine").
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
Electroconvulsive Therapy (ECT)
ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
Transcranial Magnetic Stimulation (TMS)
TMS for the treatment of treatment-resistant depression in an active major depressive episode
Ketamine
Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
Esketamine
Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
Deep Transcranial Magnetic Stimulation (dTMS)
TMS for the treatment of OCD